Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
1587 14 |
Ultima descărcare din IBN: 2022-11-11 17:56 |
Căutarea după subiecte similare conform CZU |
616-053.32-083 (1) |
Pathology. Clinical medicine (7004) |
SM ISO690:2012 SPRINCEAN, Mariana, EŢCO, Ludmila, CURTEANU, Ala, PETROV, Victor, OPALCO, Igor, BURLAC, Ala, PALADI, Elena. Dereglările neurologice ale copiilor prematuri expuşi neuroprotecţiei antenatale cu sulfat de magneziu . In: Buletin de Perinatologie, 2015, nr. 2(66), pp. 21-26. ISSN 1810-5289. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Buletin de Perinatologie | ||||||
Numărul 2(66) / 2015 / ISSN 1810-5289 | ||||||
|
||||||
CZU: 616-053.32-083 | ||||||
Pag. 21-26 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Objective of the study. Emphasizing the neurological disorders of premature children exposed to antenatal neuroptotection with magnesium sulphate. Material and methods. This study has identifi ed in retrospective and prospective analysis a sample of 291 premature children up to 34 weeks of gestation, in 2011-2014, at the Institute of Mother and Child. First study group of 122 of premature newborns (41,9%) was administrated antenatal MgSO4 and the second placebo study group of 169 newborns (58,1%) neurologically were examined at 3, 6, 9 and 12 month of age. Results. The analysis of the structure of neurologic abnormalities, identifi ed by dynamic evaluation within 12 month of life of premature newborns with less than 34 weeks of gestation period, in the group in which was administrated magnesium sulphate as antenatal neuroprotection, stipulated: major neurologic deviations – 13,5%, moderate neurologic deviations – 12,5%; minor neurologic deviations – 28,9%; psychomotorial development related to corrected age – 45,3%. Children prematurely born from fi rst MgSO4 group at the age of 12 month presented high neurologic risks in 13,5% of cases and those of second placebo group: 20,8% (t-1,5; p>0,05). Conclusions. The children of second control placebo study group demonstrated a higher rate of minor and major neurological deviations in comparance with the fi rst study group in which was antenatal administrated magnesium sulphate. |
||||||
Cuvinte-cheie premature children, magnesium sulphate, psychoneurological peculiarities, development |
||||||
|
DataCite XML Export
<?xml version='1.0' encoding='utf-8'?> <resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'> <creators> <creator> <creatorName>Sprincean, M.L.</creatorName> <affiliation>IMSP Institutul Mamei şi Copiluluii, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Eţco, L.A.</creatorName> <affiliation>IMSP Institutul Mamei şi Copiluluii, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Curteanu, A.M.</creatorName> <affiliation>IMSP Institutul Mamei şi Copiluluii, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Petrov, V.N.</creatorName> <affiliation>IMSP Institutul Mamei şi Copiluluii, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Opalco, I.</creatorName> <affiliation>IMSP Institutul Mamei şi Copiluluii, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Burlac, A.M.</creatorName> <affiliation>IMSP Institutul Mamei şi Copiluluii, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Paladi, E.I.</creatorName> <affiliation>IMSP Institutul Mamei şi Copiluluii, Moldova, Republica</affiliation> </creator> </creators> <titles> <title xml:lang='ro'>Dereglările neurologice ale copiilor prematuri expuşi neuroprotecţiei antenatale cu sulfat de magneziu </title> </titles> <publisher>Instrumentul Bibliometric National</publisher> <publicationYear>2015</publicationYear> <relatedIdentifier relatedIdentifierType='ISSN' relationType='IsPartOf'>1810-5289</relatedIdentifier> <subjects> <subject>premature children</subject> <subject>psychoneurological peculiarities</subject> <subject>development</subject> <subject>magnesium sulphate</subject> <subject schemeURI='http://udcdata.info/' subjectScheme='UDC'>616-053.32-083</subject> </subjects> <dates> <date dateType='Issued'>2015-08-13</date> </dates> <resourceType resourceTypeGeneral='Text'>Journal article</resourceType> <descriptions> <description xml:lang='en' descriptionType='Abstract'>Objective of the study. Emphasizing the neurological disorders of premature children exposed to antenatal neuroptotection with magnesium sulphate. Material and methods. This study has identifi ed in retrospective and prospective analysis a sample of 291 premature children up to 34 weeks of gestation, in 2011-2014, at the Institute of Mother and Child. First study group of 122 of premature newborns (41,9%) was administrated antenatal MgSO4 and the second placebo study group of 169 newborns (58,1%) neurologically were examined at 3, 6, 9 and 12 month of age. Results. The analysis of the structure of neurologic abnormalities, identifi ed by dynamic evaluation within 12 month of life of premature newborns with less than 34 weeks of gestation period, in the group in which was administrated magnesium sulphate as antenatal neuroprotection, stipulated: major neurologic deviations – 13,5%, moderate neurologic deviations – 12,5%; minor neurologic deviations – 28,9%; psychomotorial development related to corrected age – 45,3%. Children prematurely born from fi rst MgSO4 group at the age of 12 month presented high neurologic risks in 13,5% of cases and those of second placebo group: 20,8% (t-1,5; p>0,05). Conclusions. The children of second control placebo study group demonstrated a higher rate of minor and major neurological deviations in comparance with the fi rst study group in which was antenatal administrated magnesium sulphate. </description> <description xml:lang='ru' descriptionType='Abstract'>Цель. Выявление неврологических особенностей развития преждевременно рожденных детей, подвергшихся лечению сульфатом магния, в качестве антенатального нейропротектора. Материалы и методы. Данное исследование, проведенное в период 2011-2014 годов в Институте Матери и Ребенка, предусматривало ретроспективный и проспективный анализ 291 недоношенного ребенка, рожденные в сроках до 34-х недель. Первую группу составили 122 (41,9%) недоношенных детей, подвергавшихся антенатальному лечению MgSO4. Вторая контрольная группа (плацебо) составила 169 новорожденных (58,1%), которые проходили осмотр в возрасте 3, 6, 9 и 12 месяцев жизни. Результаты. Анализ структуры неврологических расстройств, определенных путем клинического обследования недоношенных детей в динамике в возрасте 12 месяцев с коррекцией, рожденных на сроке беременности менее 34 недель, которые прошли лечение сульфатом магния в целях антенатальной защиты, установил: тяжелые неврологические расстройства – 13,5%, неврологические расстройства средней тяжести – 12,5%; незначительные неврологические расстройства – 28,9; психомоторное развитие, соответствующее возрасту – 45,3%. У недоношенных детей из первой группы MgSO4, в возрасте 12 месяцев были выявлены высокие неврологические риски в 13,5% случаев, у детей из второй группы с плацебо лечением: 20,8% (t-1,5; p<0,05). Заключение. Былo выявленo, что у детей из второй контрольной группы чаще выявляются умеренные и тяжелые неврологические расстройства по сравнению с детьми из первой группы, которые прошли антенатальное лечение сульфатом магния.</description> </descriptions> <formats> <format>application/pdf</format> </formats> </resource>